Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 3 years
Awards & highlights
Study Summary
This trial is testing a new drug for patients with FSGS or TR-MCD. The goal is to see if it is safe and well tolerated over the long term.
Eligible Conditions
- Nephritis
- Glomerulonephritis
- Nephrotic Syndrome
- Kidney Disease
- Glomerulosclerosis
- Focal Segmental Glomerulosclerosis
- Lipoid Nephrosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence and severity of adverse events
Secondary outcome measures
Changes in estimated glomerular filtration rate (eGFR) including slope
Percent reduction in urine protein:creatinine ratio (UPCR) from baseline
Proportion of participants achieving complete remission status
+9 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: 200 mg Dose CohortExperimental Treatment1 Intervention
Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GFB-887
2019
Completed Phase 1
~70
Find a Location
Who is running the clinical trial?
Goldfinch Bio, Inc.Lead Sponsor
4 Previous Clinical Trials
225 Total Patients Enrolled
1 Trials studying Nephritis
96 Patients Enrolled for Nephritis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger